Dermscan Group, clinical test, cosmetology and drug test



	FOCUS ON 2007 Dermscan in a class of its own For over 18 years now, the Dermscan Group has kept ahead Experience Quality of services Global and customized offer: from the upstream phases of consultancy and R&D through to the final phases of utilization of the results of studies Varied protocols: standard or made-to-measure Studies carried out in the most appropriate part of the world Responses geared to your projects Beauty Security (toxicity and tolerance), efficacy (biometrology and imaging) and sensory properties (acceptability and preference) evaluation of products with Beauty claims International sites and partnerships in Europe (France, Poland), Asia (Thailand, Japan, Korea, China) and Mauritius More Health Clinical trials (phase I to IV) in the field of dermatology, la gynaecology, l'ophtalmology and odontostomatology of products with Health claims As a CRO: Clinical studies in GP surgeries or in the hospital environment Base of 6,000 clinicians Partnership with the Hôpitaux Privés du Grand Lyon (HPL) - Private Hospitals of Grand Lyon As a CIC: On-site clinical studies Generalists and specialists doctors Professionnal fittings and biometrology equipments International partnerships in Poland, Tunisia, India, Lebanon, South Africa etc. More Capture, management and statistical processing of your biomedical data Biostatistics: data capture, data management, statistical analysis Advice and expertise: support in the preparation of your trials, expertise in clinical research, audits, training More Figures 2007 turnover from orders: M€ 10 Including 33% for export Beauty: M€ 7 Health: M€ 3 Quality assurance Reinforcement of inspections and internal audits 15 activity and process audits 42 study audits Permanent quality controls to guarantee compliance with protocols, internal procedures, and to confirm that the study report is in accordance with all the raw data Internal quality training 9 training courses in the quality management system and in Good Clinical Practices were attended by 52 of our employees Continuous updating of a rich documentary base, able to guarantee the quality and traceability of trials ISO 9001 certification: 2000 was renewed following the last AFAQ-AFNOR audit in December 2007 See certification Custumized innovation An innovative offer geared to market trends in the field of cosmetics New high-tech equipment Tewameter® TM 300: TransEpidermal Waterloss (TEWL) measurement based on the diffusion principle in an open chamber Hirox®: High-tech videomicroscopy TiVi®: Study of blood microcirculation (concentration of red blood cells) by polarized light spectroscopy Halimeter®: Measurement of halitosis Impedancemeter®: Measurement of slimming (% body fat and % lean tissue) New applications Primos® Body: 3D imaging by the projection of light bands Validation of new parameters: Bust remodeling, ptosis of the lower part of the face etc. New evaluation methods Quality of life scales: Measurement of the immediate impact (BMIS) or long-term impact (WBMMS) of cosmetics on the well-being of volunteers Vigilance evaluation test: Evaluation of the energizing or relaxing effect of perfumes, in collaboration with the department of Experimental Cognitive Psychology and Neuropsychology of the University of Lyon II Measurements of skin softness: Development of a device for measuring the state of the skin's surface (friction, roughness, compressibility), in collaboration with ENSISA (Ecole Nationale Supérieure d'Ingénieurs Sud Alsace - Higher National Engineering School of South Alsace) New offers New pack of in vitro/in vivo tests on sunscreen products In accordance with the latest European and COLIPA recommendations In collaboration with HelioScreen® Labs., specializing in in vitro tests of sunscreen products Specialist in the evaluation of emerging products CosmetoTextiles evaluation: Textiles containing active ingredients of cosmetics and claiming similar benefits CosmetoFoods evaluation: Coming in various forms (capsule, yoghurt, mineral water etc.), these products claim to have effects in particular on the skin, hair and nails As a pioneer in these areas, the Dermscan Group contributes its expertise in the validation of this type of claims To come… Beauty: keeping ahead Development of the export activity in Europe Activity intensified in Eastern Europe, in particular in Poland Activity in Asia boosted By Dermscan Asia's new premises in Bangkok: 500 m2 of laboratories and equipment dedicated to clinical studies By our commercial representation: in Japan, Korea, Indonesia, Singapore, Taiwan, India, Australia and New Zealand By the establishment in 2008 of a cosmetic directive in the ASEAN zone: Very similar to European regulations Continue our R&D dynamic While still remaining the specialist in emerging sectors in France CosmetoFoods Specific approval associated with nutrition products 18 years of experience in the field of the evaluation of food supplements (capsules, energy drinks etc.) and food in the broad sense (yoghurts, soups etc.) Premises allowing for the storage of food products New sales professional specializing in food product CosmetoTextiles, « Well-being » products etc. We will also continue our other specialist activities, associated with other trend products, such as functional foods and cosmetotextiles By offering innovative methods and measuring apparatus Continuation of our scientific and technological collaboration with sponsors, hospitals and universities and our presence at conferences and scientific reviews Health: new prospects New opportunities in the hospital environment Partnership with the Hôpitaux Privés du Grand Lyon (HPL) Facilitate phase I studies Allow a special relationship with their various sites (currently two under construction) Breating life into your data! Creation of the subsidiary Statelis, in March 2007 Record, organize, structure and make coherent biomedical data Analysis and interpretation of study results Multi-centre studies and partnerships in Europe and beyond Continue international collaboration in Poland, Tunisia, India, Lebanon, South Africa etc. Put quickly in place multi-center studies Access patients who are not over-medicated